drug
belumosudil mesylate
Marketedupdated 3mo agoby Kadmon Pharmaceuticals LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(5)
approval · 5
Jul 16, 2021
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Nov 9, 2023
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Apr 10, 2024
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Dec 30, 2024
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Jan 15, 2026
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Trials studying belumosudil mesylate
- phase1A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects
- phase1A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects
- phase1A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 16, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Jul 14, 2042method-of-use (U-4014)US 12097202
- Apr 9, 2035method-of-use (U-3369)US 11311541
- Jun 20, 2034compositionUS 8357693
- Oct 7, 2033method-of-use (U-3246)US 10183931
- Oct 7, 2033method-of-use (U-3246)US 10696660
FDA exclusivities (2)
- Jul 16, 2028ODE-362Orphan Drug (7y)1.9y
- Jul 16, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that